Omicron Possess re-infection Risk : WHO

 Omicron Possess re-infection Risk : WHO

According to World Health Organization (WHO), Omicron COVID variant possess a high risk of infection worldwide. Researchers in South Africa and around the world are conducting studies to better understand many aspects of Omicron and will continue to share the findings of these studies as they become available.  It is not yet clear whether Omicron is more transmissible from person to person compared to other variants, including Delta. The number of people testing positive has risen in areas of South Africa affected by this variant, but epidemiologic studies are underway to understand if it is because of Omicron or other factors.  

Dr Tedros Adhanom Ghebreyesus, Director General, WHO said that the variant was detected in South Africa earlier this month with initial evidence suggesting that it has a higher re-infection risk. South Africa has been praised for its prompt reporting of the variant. “Omicron has an unprecedented number of spike mutations, some of which are concerning for their potential impact on the trajectory of the pandemic.”

The Severity of disease is not yet clear whether infection with Omicron causes more severe disease compared to infections with other variants, including Delta.  Preliminary data suggests that there are increasing rates of hospitalization in South Africa, but this may be due to increasing overall numbers of people becoming infected, rather than a result of specific infection with Omicron.  There is currently no information to suggest that symptoms associated with Omicron are different from those from other variants.  Initial reported infections were among university students—younger individuals who tend to have more mild disease—but understanding the level of severity of the Omicron variant will take days to several weeks.  All variants of COVID-19, including the Delta variant that is dominant worldwide, can cause severe disease or death, in particular for the most vulnerable people, and thus prevention is always key. 

WHO further briefed that the effectiveness of prior SARS-CoV-2 infection preliminary evidence suggests there may be an increased risk of re-infection with Omicron,that is people who have previously had COVID-19 could become re-infected more easily, as compared to other variants of concern, but information is limited. 

Vaccines remain critical to reducing severe disease and death, including against the dominant circulating variant, Delta. Current vaccines remain effective against severe disease and death. WHO is working with technical partners to understand the potential impact of this variant on our existing countermeasures, including vaccines.

The widely used PCR tests continue to detect infection, including infection with Omicron, as we have seen with other variants as well. Studies are ongoing to determine whether there is any impact on other types of tests, including rapid antigen detection tests, explained WHO  

Corticosteroids and IL6 Receptor Blockers will still be effective for managing patients with severe COVID-19. Other treatments will be assessed to see if they are still as effective given the changes to parts of the virus in the Omicron variant. 

WHO encourages countries to contribute the collection and sharing of hospitalized patient data through the WHO COVID-19 Clinical Data Platform, to rapidly describe clinical characteristics and patient outcomes. WHO’s TAG-VE will continue to monitor and evaluate the data as it becomes available and assess how mutations in Omicron alter the behaviour of the virus.  

As Omicron has been designated a Variant of Concern, there are several actions WHO recommends countries to undertake, including enhancing surveillance and sequencing of cases;  sharing genome sequences on publicly available databases, such as GISAID; reporting initial cases or clusters to WHO; performing field investigations and laboratory assessments to better understand if Omicron has different transmission or disease characteristics, or impacts effectiveness of vaccines, therapeutics, diagnostics or public health and social measures.  Countries should continue to implement the effective public health measures to reduce COVID-19 circulation overall, using a risk analysis and science-based approachThey should increase some public health and medical capacities to manage an increase in cases.  WHO is providing countries with support and guidance for both readiness and response.  

In addition, it is vitally important that inequities in access to COVID-19 vaccines are urgently addressed to ensure that vulnerable groups everywhere, including health workers and older persons, receive their first and second doses, alongside equitable access to treatment and diagnostics.   The most effective steps individuals can take to reduce the spread of the COVID-19 virus is to keep a physical distance of at least 1 metre from others; wear a well-fitting mask; open windows to improve ventilation; avoid poorly ventilated or crowded spaces; keep hands clean; cough or sneeze into a bent elbow or tissue; and get vaccinated when it’s their turn.  

Digiqole ad

Leave a Reply

Your email address will not be published.